AZN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AstraZeneca PLC (AZN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst ratings, hedge fund interest, and pipeline developments make it a compelling investment opportunity despite some minor technical weaknesses.
The stock shows mixed technical signals. While moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD is negative and expanding downward (-0.204), and RSI is neutral at 48.115. The stock is trading near its support level (S1: 198.42), which could provide a buying opportunity. However, the price trend lacks clear momentum.
Hedge funds are significantly increasing their positions in AstraZeneca, with a 166.61% rise in buying activity over the last quarter.
Analysts have consistently raised price targets, citing strong pipeline developments, positive Phase 3 data, and sector-leading earnings growth.
Financial performance in Q4 2025 shows robust growth in revenue (+4.11% YoY), net income (+55.07% YoY), and EPS (+55.21% YoY).
The MACD indicator suggests a bearish trend in the short term.
Gross margin declined by -2.70% YoY in Q4 2025, which could indicate some cost pressures.
Insider trading activity is neutral, with no significant trends to support bullish sentiment.
In Q4 2025, AstraZeneca reported strong financial growth: revenue increased by 4.11% YoY to $15.503 billion, net income surged by 55.07% YoY to $2.326 billion, and EPS rose by 55.21% YoY to $1.49. However, gross margin dropped slightly to 78.89%, down -2.70% YoY.
Analysts are overwhelmingly positive on AstraZeneca. Recent updates include multiple price target increases, with Citi raising its target to 18,000 GBp and Morgan Stanley maintaining an Overweight rating while citing strong pipeline developments and sector-leading earnings growth. Goldman Sachs also highlighted positive Phase 3 data as a game-changer for the stock.
